促进多样性与平行化学的最优化合物下选
Optimal compound downselection to promote diversity and parallel chemistry
AI总结:
本文扩展化合物下选框架 SPARROW,引入合成失败风险、分子多样性和平行化学约束,使其更贴近真实药物发现决策并选出适合并行合成的多样化批次。
摘要:
早期药物发现和分子设计项目通常遵循迭代式的设计—合成—测试循环。在所有可能的候选化合物中选择要合成的化合物,是这些设计循环固有的复杂决策,必须权衡多种因素。我们在算法下选框架 SPARROW 的基础上进行构建,该框架考虑合成成本、合成可行性和化合物效用,并对其加以扩展,以处理与合成失败风险、分子多样性和平行化学能力相关的其他关键因素。这些设计考虑进一步使算法化合物选择与该决策过程的真实复杂性保持一致,使 SPARROW 能够捕捉通常依赖资深化学家直觉的更广泛原则集。将这些公式应用于一个示例性案例研究,突显了 SPARROW 促进选择多样化化合物批次的能力,这些化合物的合成适合采用平行化学。
英文摘要:
Early stage drug discovery and molecular design projects often follow iterative design-make-test cycles. The selection of which compounds to synthesize from all possible candidate compounds is a complex decision inherent to these design cycles that must weigh multiple factors. We build upon the algorithmic downselection framework SPARROW that considers synthetic cost, synthetic feasibility, and compound utility, extending it to address additional critical factors related to the risk of synthesis failure, molecular diversity, and parallel chemistry capabilities. These design considerations further align algorithmic compound selection with the true complexity of this decision-making process, allowing SPARROW to capture a broader set of principles typically reliant on expert chemist intuition. The application of these formulations to an exemplary case study highlights SPARROW's ability to promote the selection of diverse batches of compounds whose syntheses are amenable to parallel chemistry.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。